

January 15, 2026



Adaptin Bio to Present at the 2026 Sequire Investor Summit in Puerto Rico

CHARLOTTE, N.C., Jan. 15, 2026 (GLOBE NEWSWIRE) - [Adaptin Bio, Inc.](#) ("Adaptin" or the "Company"), a biotechnology company focused on developing precision cancer therapies with targeted delivery to the brain and other tissues, today announced that it will be presenting at the upcoming Sequire Investor Summit 2026. The fourth edition of the Sequire Investor Summit is scheduled to be held on January 20th-22nd, 2026, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.

"We look forward to the Sequire Investor Summit and the opportunity to meet with investors and update them on our novel targeted drug delivery platform as well as our lead product candidate APTN-101 for the treatment of glioblastoma multiforme (GBM)." said Michael Roberts, Chief Executive Officer of Adaptin. "We believe that 2026 will be a transformational year for the Company, as we advance APTN-101 into clinical development, and as we expect our common stock to begin trading on OTC Markets."

Puerto Rico is home to many family offices, funds and wealthy investors due to its favorable tax environment.

Please review the program agenda for the day and time of the Adaptin Bio presentation. For more information about the Sequire Investor Summit, including registration and other conference details, please visit the official event website at puertorico.srax.com

About Adaptin Bio, Inc.

Adaptin Bio, Inc. is a biotechnology company developing novel therapies for oncology and central nervous system disorders. Its mission is to improve patient outcomes in difficult-to-treat cancers by improving and enhancing drug delivery to the brain and other tissues. The Company's proprietary Brain Bispecific T cell Engager (BRiTE) technology, powering investigational cancer therapeutic APTN-101, was developed by researchers at the Department of Neurosurgery at Duke University. APTN-101 is FDA-cleared for a Phase 1 clinical trial in glioblastoma (GBM), and other indications are being considered for future studies. For more information, visit www.adaptinbio.com.

Caution Regarding Forward Looking Statements:

Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. These forward-looking statements may include information concerning possible or projected future business operations. Such statements are often characterized by the use of qualified words (and their derivatives) such as "anticipate," "believe," "continues," "could," "design," "estimate," "expect," "goals," "intend," "looking," "may," "objectives," "opportunity," "outlook," "plan," "positioned," "potential," "project," "seek," "should," "target," "will," "would," or other statements concerning opinions or judgments of the Company and its management about future events. Actual results might differ materially from those explicit or implicit in the

forward-looking statements. Important factors that could cause actual results to differ materially include: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern and develop our product candidate as anticipated; our ability to control costs associated with our operations; intellectual property risks; risks of our clinical trials, including, but not limited to, the timing, delays, costs, design, initiation, enrollment, and results of such trials; any delays in regulatory review and approval of product candidates in development; reliance on third parties to supply drug substance and drug product for our clinical trials and preclinical studies, and produce commercial supplies of product candidates; the potential advantages of our product candidate; our competitive position; risks related to our potential quotation on the OTC Markets and ability to develop a market for common stock; our ability to maintain our culture and recruit, integrate and retain qualified personnel and advisors, including on our Board of Directors; volatility and uncertainty in the global economy and financial markets; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and other risks and uncertainties set forth from time to time in our filings with the Securities and Exchange Commission. Adaptin assumes no obligation and does not intend to update these forward-looking statements except as required by law.

Investor Contact:

1-800-428-8070

investor@adaptinbio.com